Prediction of a high-risk group based on postoperative nadir CA-125 levels in patients with advanced epithelial ovarian cancer

Journal of Gynecologic Oncology

Volumn 22, Issue 4, 2011, Pages 269-274

  Kang, Sokbom ^a   Kim, Tae Joong ^b   Seo, Sang Soo ^a   Kim, Byoung Gie ^b   Bae, Duk Soo ^b   Park, Sang Yoon ^a  

^a National Cancer Center   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Biomarker; CA 125; Ovarian cancer; Prognosis; Progression free survival; Risk factor

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; NADIR CA 125 ANTIGEN; PACLITAXEL; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ADVANCED EPITHELIAL OVARY CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; POSTOPERATIVE PERIOD; PREDICTION; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC;

EID: 84863298525     PISSN: 20050380     EISSN: 20050399     Source Type: Journal    
DOI: 10.3802/jgo.2011.22.4.269     Document Type: Article

References (12)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194-200.
3. Armstrong DK, Brady MF. Intraperitoneal therapy for ovarian cancer: a treatment ready for prime time. J Clin Oncol 2006; 24:4531-3.
4. Olt GJ, Berchuck A, Bast RC Jr. Gynecologic tumor markers. Semin Surg Oncol 1990;6:305-13.
5. Skates SJ, Horick NK, Moy JM, Minihan AM, Seiden MV, Marks JR, et al. Pooling of case specimens to create standard serum sets for screening cancer biomarkers. Cancer Epidemiol Biomarkers Prev 2007;16:334-41.
6. Makar AP, Kristensen GB, Kaern J, Bormer OP, Abeler VM, Trope CG. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis. Obstet Gynecol 1992;79:1002-10.
7. Crawford SM, Peace J. Does the nadir CA-125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary? Ann Oncol 2005;16:47-50.
8. Juretzka MM, Barakat RR, Chi DS, Iasonos A, Dupont J, Abu-Rustum NR, et al. CA-125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Gynecol Oncol 2007;104:176-80.
9. Markman M, Liu PY, Rothenberg ML, Monk BJ, Brady M, Alberts DS. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. J Clin Oncol 2006;24:1454-8.
10. Prat A, Parera M, Peralta S, Perez-Benavente MA, Garcia A, Gil-Moreno A, et al. Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer. Ann Oncol 2008;19:327-31.
11. Kang S, Seo SS, Park SY. Nadir CA-125 level is an independent prognostic factor in advanced epithelial ovarian cancer. J Surg Oncol 2009;100:244-7.
12. Pignata S, Perrone F, Di Maio M, Gallo C, De Placido S. In Reply. J Clin Oncol 2005;23:2436-7.